Merck Sharp + Dohme Corp.

Abdelghani Achab

Derun Li

Xavier Fradera

Hua Zhou

Hongjun Zhang

Yongxin Han

Meredeth Ann McGowan

Kun Liu

Yongqi Deng

Wensheng Yu

Nunzio Sciammetta

David L Sloman

Joey Lee Methot

Jason David Katz

Qinglin Pu

Catherine M White

Matthew Christopher

Joseph A Kozlowski

Jared N Cumming

Anandan Palani

Shuwen He

Gerald Wayne Shipps, Jr

Liangqin Guo

Craig R Gibeau

Charles A Lesburg

Shimin Xu

Min Lu

Francesc Xavier Fradera Llinas

Indu T Bharathan

Symon Gathiaka

Rachel L Palte

Neville J Anthony

Michael D Altman

David James Witter

Jongwon Lim

Solomon D Kattar

Guoqing Li

Purakkattle J Biju

Rong Zhang

Jianmin Fu

Peter Orth

Johannes H Voigt

Christian Fischer

Matthew Lloyd Childers

Kin Chiu Fong

Xiaohua Huang

Changwei Mu

Chaomin Li

Brett A Hopkins

Yudith Garcia

Matthew J Mitcheltree

Xiansheng Leng

Sixing Zhang

Ravi P Nargund

Timothy J Guzi

Sung-Sau So

Alan B Cooper

Phieng Siliphaivanh

Zhi-Cai Shi

Jing Su

Feng Shi

John W Lampe

Binyuan Sun

Hakan Gunaydin

Erin F DiMauro

David Jonathan Bennett

Liping Yang

Liang Zhu

Gerald W Shipps

Kathryn Ann Lipford

Cliff C Cheng

Ning Fu

Ravi Kurukulasuriya

Xiaoli Zhao

Sie-Mun Lo

Timothy A Cernak

Yabin Li

Zachary G Brill

Chunrui Sun

Sulagna Sanyal

Meredeth A Mcgowan

Brandon A Vara

Clifford Cheng

Baijun Ye

Xiaona Wang

Xioahua Huang

Kyle Ann Soucy

Xichao Wang

Jonathan D Bennett

Bridget A Becker

Hua Zhao

Lianqin Guo

Clifford C Cheng

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Described herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.

Arginase inhibitors and methods of use

Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.

Described herein are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein A, R, R, R, W, X, Y, Z, m, n and p are as defined herein. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.

Spirotricycle RIPK1 inhibitors and methods of uses thereof

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases. 

The instant invention provides compounds of formulas Ia and Ib which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer. 

Purine inhibitors of human phosphatidylinositol 3-kinase delta

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I) Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted phenyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted N'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof:  Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

Growing community of inventors

Melrose, MA, United States of America

Abdelghani Achab